A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
about
Systemic Chemotherapy in Advanced Pancreatic CancerMolecular Targeted Intervention for Pancreatic CancerCXCR2: a target for pancreatic cancer treatment?Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatmentMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Smarter drugs emerging in pancreatic cancer therapy.Long-time survival of a patient with metastatic pancreatic cancer: a case reportLooking to the future: biomarkers in the management of pancreatic adenocarcinoma.A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy.Sunitinib malate for the treatment of pancreas malignancies--where does it fit?Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
P2860
Q26750440-F35FB3A6-EB16-4560-9406-A3D1DDEB89DAQ26798453-1DD7E972-CD6C-4146-8363-C0DF6B0D0DA2Q27021588-503A4F22-F155-4601-A1F2-A80FD343328BQ28074428-520D37E5-D179-4B84-B6F4-DFC379AAE5C5Q28082919-38F1B78A-01DF-4EDF-85DA-A993E65F24EAQ33415850-CB9F4A6E-CBB2-48EA-82E1-6AFC6AEA25FAQ33633424-AB97C291-BCDA-4566-AA61-36A8ECF55989Q34410212-18F97C3F-2281-4C93-AE25-4175F782E541Q35225648-63BCF024-295D-453D-A8EB-AF732AD2362CQ35297202-E6320839-DFBF-4141-9EC8-B7C3CBF40450Q36437111-4A0A77B5-23DE-4EB1-BCEE-564F940B2CCFQ36550798-202DEC86-0E35-4BFB-8B53-19DD24614FA5Q37111183-6B2B61D2-F164-44F5-8E8E-9883FBF516D9Q37582596-164CAA9D-BE67-421C-A004-DFD455820842Q37617955-A2F75BCD-1E80-4512-8EEB-DEE956CB94C8Q37734570-B234E3A7-3B8A-4249-BE88-73F2E86D9419Q38086310-32D7228F-7AAC-417F-B50A-9DC22B44AC62Q38165930-53860F02-A6A0-4D79-BAEF-F99A69089F29Q38577917-D6100501-58B0-488F-88B9-3D326BF1F608Q38627885-E64D812D-955F-4C25-BABA-B5771E0B660AQ38645930-4774C32E-1358-40C8-BC25-42C0A076A04CQ38684978-9BFF1C39-2A3A-42E8-8A14-DD9DE938213BQ38971815-80967ACC-972C-4E9F-9615-CB550BEEDE61Q39635470-E470CD7A-E464-42BE-94C3-86E49184F141Q58799265-00E8F5ED-C50C-478B-9678-D882652F55CCQ58819336-6D0A7B97-CBEF-423B-8173-B48EBE7DE5A1
P2860
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@ast
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@en
type
label
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@ast
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@en
prefLabel
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@ast
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@en
P2093
P2860
P1433
P1476
A Cancer and Leukemia Group B ...... adenocarcinoma (CALGB 80603).
@en
P2093
Donna Hollis
Donna Niedzwiecki
Eileen M O'Reilly
Ghassan K Abou-Alfa
Hedy L Kindler
Kathe Douglas
Margaret Hall
Richard L Schilsky
Richard M Goldberg
Tanios Bekaii-Saab
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0152
P577
2010-12-10T00:00:00Z